IBRX Research and Charts

IBRX - ImmunityBio Inc Ordinary Shares (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2025-01-03)

Last 2.81	Change ⇑ +0.24 (+9.34%)	Volume 4,830,202
	Open 2.62	High 2.81	Low 2.59

8EMA (Daily) 2.73	40EMA (Daily) 3.64	50EMA (Daily) 3.78	STO (Daily) 15.641	MACD Hist (Daily) 0.034
8EMA (Weekly) 3.525	40EMA (Weekly) 4.43	50EMA (Weekly) 4.46	STO (Weekly) 10.877	MACD Hist (Weekly) -0.410


Company Profile
ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term immunological memory.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.